Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib with Phesgo and Nab-paclitaxel in HER2+ PIK3CA-mutated Early Breast Cancer
NCT07245797Phase 2Not yet recruiting
- Sponsor
- Zhimin Shao
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of inavolisib in breast cancer, sponsored by Zhimin Shao. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07245797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07245797.